2. Academic Validation
  3. Single-fraction radiotherapy with a bioactive depot of CD39 blockade eradicates malignant tumors

Single-fraction radiotherapy with a bioactive depot of CD39 blockade eradicates malignant tumors

  • J Control Release. 2026 Mar 10:391:114632. doi: 10.1016/j.jconrel.2026.114632.
Chunlian Ye 1,  Yun Zheng 2,  Huilan He 2,  Jinlong Ji 1,  Liang Liu 1,  Yu Sun 1,  Yuwei Peng 2,  Shenqiang Wang 3,  Ying Zhang 4,  Zhiyuan Zhong 5
Affiliations

Affiliations

  • 1 College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.
  • 2 College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China; College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • 3 College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • 4 College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China; College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China. Electronic address: [email protected].
  • 5 College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China; College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China. Electronic address: [email protected].
PMID: 41539607 DOI: 10.1016/j.jconrel.2026.114632
Abstract

The efficacy of radio-immunotherapy is generally limited by adaptive resistance mechanisms that create an immunosuppressive tumor microenvironment. The molecular drivers of this radio-resistance remain poorly defined. Here we identify the ectonucleotidase CD39 as a critical driver of radiotherapy (RT)-induced immunosuppression. We show that RT robustly upregulates CD39 on tumor cells and tumor-infiltrating immune cells, creating an adenosine-rich tumor microenvironment that promotes immune evasion. Pharmacological inhibition of CD39 with POM-1 reverses this immunosuppression, synergizing with RT to enhance anti-tumor immunity. Furthermore, we engineer an immuno-gel (POM-1@iGel) for sustained local CD39 inhibition and concurrent immune stimulation. A single intratumoral injection of POM-1@iGel in combination with single-fraction RT establishes durable systemic anti-tumor immunity with immunological memory and leads to complete tumor regression in a murine colorectal Cancer model. These findings elucidate a critical mechanism of RT-induced immune escape and present a rational, scalable strategy to overcome RT-induced immunosuppression and boost radio-immunotherapy in solid tumors.

Keywords

CD39 blockade; Cancer immunotherapy; Immunosuppressive marker; Injectable hydrogels; Systemic anti-tumor immunity.

Figures
Products